Skip to main content

Partnerships

Cidara has a proven track record of building successful partnerships, and we welcome your inquiries. Here are our existing partnerships:

Janssen Pharmaceuticals

Cidara and Janssen Pharmaceuticals (Janssen) have a worldwide license and collaboration agreement to develop and commercialize drug-Fc conjugates (DFCs) for the prevention of seasonal and pandemic influenza. Under the collaboration, Cidara will be responsible for the development and manufacturing of CD388 into the clinic and through Phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. CD388 is currently being tested in a Phase 2a clinical trial (NCT05523089) in healthy volunteers.

Cidara and Mundipharma have a strategic partnership to develop and commercialize rezafungin for the treatment and prevention of invasive fungal disease in all markets outside of the U.S. and Japan, which are retained by Cidara. Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of Pain & Supportive Care and Consumer Healthcare as well as other severe and debilitating disease areas. Mundipharma submitted a marketing authorization application (MAA) for rezafungin to the European Medicines Agency (EMA) for the treatment of invasive candidiasis in adult patients. The MAA was accepted on August 22, 2022.

Cidara and Melinta Therapeutics have a license agreement under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the U.S. Melinta provides innovative therapies to people impacted by acute and life-threatening illnesses. With an unsurpassed commitment to providers and the patients they serve, Melinta works to ensure that all people who need its therapies can receive them. Cidara, on behalf of the partnership, submitted a New Drug Application (NDA) for rezafungin to the U.S. FDA on July 22, 2022, for the treatment of candidemia and invasive candidiasis in adult patients, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validation.

Inquiries

Cidara welcomes inquiries regarding potential opportunities for collaboration across discovery, development and commercialization. For more details, please fill out the form below or email: info@cidara.com.